U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07525141) titled 'A Study of JNJ-1761981 in Participants With Solid Tumors' on April 06.
Brief Summary: The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Intervention:
DRUG: JNJ-1761981
JNJ-1761981 will be administered intratumorally.
DRUG: Cetrelimab
Cetrelimab will be administered intravenously.
Recruitment Status: NOT_YET_RECRUITING
Sp...